PDF
Abstract
The expression of multidrug resistant proteins in bladder cancer and clinical implication was studied. Expression of multidrug-associated protein (MRP), P-glycoprotein (P-gp), P53 and Bcl-2 proteins were detected by using immunohistochemical method in 40 specimens of bladder transitional cell carcinoma. The results showed that the positive rate of MRP, P-gp, P53 and Bcl-2 was 52. 5 %, 57. 5 %, 47. 5 % and 62. 5 % respectively. The positive rate of MRP, P-gp, P53 and Bcl-2 in the grade I, I andI of tumors was 46. 3 %, 38. 5 %, 38. 5 %, 23. 1 %; 52. 9 %, 39. 8 %, 47. 1 %, 76. 4 %; 60. 0 %, 80. 0 %, 60. 0 %, 90. 0 % respectively. The positive rate of MRP, P-gp, P53 and Bcl-2 in 24 primary tumor specimens was 37. 5 %, 41. 7 %, 33. 3 %, 45. 8 % and that in 16 cases in recurrent specimens receiving chemotherapy 75. 0 %, 81. 3 %, 68. 8 %, 87. 5 % respectively. It was suggested the positive rate of MRP, P-gp, P53 and Bcl-2 was increased with the advance of tumor grade. The positive rate of four proteins in all recurrent cases was significantly increased (P<0. 05). The expression of MRP, P-gp, P53 and Bcl-2 proteins might be the important factors for chemotherapy failure.
Keywords
bladder neoplasms
/
multiple drug resistance
/
apoptosis
Cite this article
Download citation ▾
Chen Zhong, Zhang Yongxing, Zhang Xu, Du Guanghui, Yang Weiming, Hu Ziquan, Li Jiagui, Zhang Yongshang.
Expression of multidrug-associated protein, P-glycoprotein, P53 and Bcl-2 proteins in bladder cancer and clinical implication.
Current Medical Science, 2001, 21(1): 56-58 DOI:10.1007/BF02888038
| [1] |
RhodesT, BarrandM A, TwentymanP R, et al.. Modification by brefeldin A, bafilomycin Al, and 7-chloro-4-nitrobenz-2-oxa-1, 3-diazole(NBD) of cellular accumulation and intracellular distribution of anthracyclines in the non-P-glycoprotein-mediated multidrug-resistant cell line COR-L23/R. Br J Cancer, 1994, 70(1): 60-60
|
| [2] |
CliffordS C, NealD E, LuneeJ. Alterations in express of the multidrug resistance-associated protein (MRP) gene in high-grade transitional carcinoma of the bladder. Br J Cancer, 1996, 73: 659-659
|
| [3] |
LoweS W, RuleyH E, JacksT, et al.. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 1993, 74: 957-957
|
| [4] |
MiyashitaT, ReedJ. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 1993, 81: 151-151
|
| [5] |
WangQ, BeckW T. Transcripional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type P53. Cancer Res, 1998, 58(24): 5762-5762
|
| [6] |
StraussB E, ShivakumarC, DebS P, et al.. The MDR1 downstream promoter contains sequence-specific binding sites for wild-type P53. Biochem Biophys Res Commun, 1995, 217(3): 825-825
|
| [7] |
OshikaY, NakamuraM, TokunagaT, et al.. Multidrug resistance-associated protein and mutant P53 protein expression in non-small cell lung cancer. Mod Pathol, 1998, 11(11): 1059-1059
|
| [8] |
LinnS C, HonkoopA H, HoekmanK, et al.. P53 and Pglycoprotein are often co-expressed are associated with poor prognosis in breast cancer. Br J Cancer, 1996, 74: 63-63
|
| [9] |
EidH, GulyasM, GecziL, et al.. Expression of Bcl-2 in testicular carcinoma: correlation with tumor progression and MDR1/pgp. Cancer, 1998, 84: 301-301
|
| [10] |
SlapakC A, FracassoP M, MartellR L, et al.. Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistance murine erythroleukemia cells. Cancer Res, 1994, 54: 5607-5607
|
